NCT06974474View on ClinicalTrials.gov

Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.

PHASE4RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

November 27, 2025

Study Completion Date

May 27, 2027

Conditions
Psoriasis Arthritis
Interventions
DRUG

Guselkumab

Guselkumab

Trial Locations (1)

00128

RECRUITING

Immunorheumatology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Campus Bio-Medico

OTHER